KRAS and breast cancer: As discussed above, the experimental outcomes also may potentially be affected by compensatory upregulation of other PFKFB isoforms such as PFKFB4 which likely explains the differences that we observed in the growth of the more gradual K-ras-driven lung tumor model relative to the Erbb2 mammary tumor model.